Abnormal endocrine pancreas function at birth in cystic fibrosis ferrets

Journal of Clinical Investigation

Volumn 122, Issue 10, 2012, Pages 3755-3768

  Olivier, Alicia K ^a   Yi, Yaling ^a   Sun, Xingshen ^a   Sui, Hongshu ^a   Liang, Bo ^a   Hu, Shanming ^a   Xie, Weiliang ^a   Fisher, John T ^a   Keiser, Nicholas W ^a   Lei, Diana ^a   Zhou, Weihong ^a   Yan, Ziying ^a   Li, Guiying ^a   Evans, Turan I A ^a   Meyerholz, David K ^a   Wang, Kai ^b   Stewart, Zoe A ^a   Norris, Andrew W ^a   Engelhardt, John F ^a  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLUCAGON; GLUCOSE; INSULIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CULTURE; CONTROLLED STUDY; CYSTIC FIBROSIS; DISEASE ASSOCIATION; DISEASE COURSE; FERRET; GENOTYPE; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RELEASE; NEWBORN; NONHUMAN; PANCREAS ISLET DISEASE; PANCREATITIS; PRIORITY JOURNAL;

ANIMALS; ANIMALS, NEWBORN; APOPTOSIS; CELLS, CULTURED; CYSTIC FIBROSIS; DIABETES MELLITUS; DILATATION, PATHOLOGIC; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; FERRETS; FIBROSIS; GENE KNOCKOUT TECHNIQUES; GLUCAGON; GLUCOSE; GLUCOSE INTOLERANCE; HYPERGLYCEMIA; INSULIN; ISLETS OF LANGERHANS; MALE; PANCREAS, EXOCRINE; PANCREATIC DUCTS; PANCREATITIS; SPECIES SPECIFICITY;

EID: 84867166324     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI60610     Document Type: Article

References (72)

1. Moran A, et al. Epidemiology, pathophysiology, and prognostic implications of cystic fibrosisrelated diabetes: a technical review. Diabetes Care. 2010;33(12):2677-2683.
2. Hameed S, Jaffe A, Verge CF. Cystic fibrosis related diabetes (CFRD) - the end stage of progressive insulin deficiency. Pediatr Pulmonol. 2011;46(8):747-760.
3. Lanng S, Thorsteinsson B, Nerup J, Koch C. Influence of the development of diabetes mellitus on clinical status in patients with cystic fibrosis. Eur J Pediatr. 1992;151(9):684-687.
4. Bismuth E, et al. Glucose tolerance and insulin secretion, morbidity, and death in patients with cystic fibrosis. J Pediatr. 2008;152(4):540-545.e1.
5. Koch C, et al. Presence of cystic fibrosis-related diabetes mellitus is tightly linked to poor lung function in patients with cystic fibrosis: data from the European Epidemiologic Registry of Cystic Fibrosis. Pediatr Pulmonol. 2001;32(5):343-350.
6. Brodsky J, Dougherty S, Makani R, Rubenstein RC, Kelly A. Elevation of 1-hour plasma glucose during oral glucose tolerance testing is associated with worse pulmonary function in cystic fibrosis. Diabetes Care. 2011;34(2):292-295.
7. Cheung MS, et al. Growth in children with cystic fibrosis-related diabetes. Pediatr Pulmonol. 2009; 44(12):1223-1225.
8. Moran A, Dunitz J, Nathan B, Saeed A, Holme B, Thomas W. Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality. Diabetes Care. 2009;32(9):1626-1631.
9. Ripa P, Robertson I, Cowley D, Harris M, Masters IB, Cotterill AM. The relationship between insulin secretion, the insulin-like growth factor axis and growth in children with cystic fibrosis. Clin Endocrinol (Oxf). 2002;56(3):383-389.
10. Moran A, Doherty L, Wang X, Thomas W. Abnormal glucose metabolism in cystic fibrosis. J Pediatr. 1998;133(1):10-17.
11. De Schepper J, Hachimi-Idrissi S, Smitz J, Dab I, Loeb H. First-phase insulin release in adult cystic fibrosis patients: correlation with clinical and biological parameters. Horm Res. 1992;38(5-6):260-263.
12. Mohan K, et al. Mechanisms of glucose intolerance in cystic fibrosis. Diabet Med. 2009;26(6):582-588.
13. Mohan K, Israel KL, Miller H, Grainger R, Ledson MJ, Walshaw MJ. Long-term effect of insulin treatment in cystic fibrosis-related diabetes. Respiration. 2008;76(2):181-186.
14. Dobson L, Hattersley AT, Tiley S, Elworthy S, Oades PJ, Sheldon CD. Clinical improvement in cystic fibrosis with early insulin treatment. Arch Dis Child. 2002;87(5):430-431.
15. Moran A, et al. Insulin sensitivity in cystic fibrosis. Diabetes. 1994;43(8):1020-1026.
16. Durie PR, Forstner GG. Pathophysiology of the exocrine pancreas in cystic fibrosis. J R Soc Med. 1989;82(suppl 16):2-10.
17. Iannucci A, Mukai K, Johnson D, Burke B. Endocrine pancreas in cystic fibrosis: an immunohistochemical study. Hum Pathol. 1984;15(3):278-284.
18. Lohr M, et al. Cystic fibrosis associated islet changes may provide a basis for diabetes. An immunocytochemical and morphometrical study. Virchows Arch A Pathol Anat Histopathol. 1989;414(2):179-185.
19. O'Riordan SM, Dattani MT, Hindmarsh PC. Cystic fibrosis-related diabetes in childhood. Horm Res Paediatr. 2010;73(1):15-24.
20. Moran A, Phillips J, Milla C. Insulin and glucose excursion following premeal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care. 2001;24(10):1706-1710.
21. Street ME, et al. Insulin production and resistance in cystic fibrosis: effect of age, disease activity, and genotype. J Endocrinol Invest. 2012;35(3):246-253.
22. Moran A, et al. Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care. 2010;33(12):2697-2708.
23. Austin A, Kalhan SC, Orenstein D, Nixon P, Arslanian S. Roles of insulin resistance and beta-cell dysfunction in the pathogenesis of glucose intolerance in cystic fibrosis. J Clin Endocrinol Metab. 1994;79(1):80-85.
24. Hardin DS, LeBlanc A, Para L, Seilheimer DK. Hepatic insulin resistance and defects in substrate utilization in cystic fibrosis. Diabetes. 1999; 48(5):1082-1087.
25. Wilmshurst EG, et al. Endogenous and exogenous insulin responses in patients with cystic fibrosis. Pediatrics. 1975;55(1):75-82.
26. Lombardo F, et al. Natural history of glucose tolerance, beta-cell function and peripheral insulin sensitivity in cystic fibrosis patients with fasting euglycemia. Eur J Endocrinol. 2003;149(1):53-59.
27. Lanng S, Thorsteinsson B, Roder ME, Nerup J, Koch C. Insulin sensitivity and insulin clearance in cystic fibrosis patients with normal and diabetic glucose tolerance. Clin Endocrinol (Oxf). 1994;41(2):217-223.
28. Yung B, Noormohamed FH, Kemp M, Hooper J, Lant AF, Hodson ME. Cystic fibrosis-related diabetes: the role of peripheral insulin resistance and betacell dysfunction. Diabet Med. 2002;19(3):221-226.
29. Cucinotta D, et al. No changes of insulin sensitivity in cystic fibrosis patients with different degrees of glucose tolerance: an epidemiological and longitudinal study. Eur J Endocrinol. 1994;130(3):253-258.
30. van Haren EH, Hopman WP, Jansen JB, Rosenbusch G, Lamers CB, van Herwaarden CL. Increased plasma cholecystokinin levels and small gall bladders in adult patients with cystic fibrosis. Clin Sci (Lond). 1991;81(1):85-89.
31. Kuo P, et al. Gastric emptying, incretin hormone secretion, and postprandial glycemia in cystic fibrosis - effects of pancreatic enzyme supplementation. J Clin Endocrinol Metab. 2011;96(5):E851-E855.
32. Ross SA, Morrison D, McArthur RG. Hypersecretion of gastric inhibitory polypeptide in nondiabetic children with cystic fibrosis. Pediatrics. 1981; 67(2):252-254.
33. Poretsky L. Principles of Diabetes Mellitus. 2nd ed. Boston, Massachusetts, USA: Springer; 2010.
34. Sauerwein HP, Schols AM. Glucose metabolism in chronic lung disease. Clin Nutr. 2002;21(5):367-371.
35. Stalvey MS, Flotte TR. Endocrine parameters of cystic fibrosis: back to basics. J Cell Biochem. 2009; 108(2):353-361.
36. Stalvey MS, et al. Cystic fibrosis transmembrane conductance regulator deficiency exacerbates islet cell dysfunction after beta-cell injury. Diabetes. 2006; 55(7):1939-1945.
37. Fisher JT, Zhang Y, Engelhardt JF. Comparative biology of cystic fibrosis animal models. Methods Mol Biol. 2011;742:311-334.
38. Keiser NW, Engelhardt JF. New animal models of cystic fibrosis: what are they teaching us? Curr Opin Pulm Med. 2011;17(6):478-483.
39. Sun X, et al. Adeno-associated virus-targeted disruption of the CFTR gene in cloned ferrets. J Clin Invest. 2008;118(4):1578-1583.
40. Sun X, et al. Disease phenotype of a ferret CFTR-knockout model of cystic fibrosis. J Clin Invest. 2010; 120(9):3149-3160.
41. Lindblad A, Glaumann H, Strandvik B. Natural history of liver disease in cystic fibrosis. Hepatology. 1999;30(5):1151-1158.
42. Scher H, Bishop WP, McCray PB. Ursodeoxycholic acid improves cholestasis in infants with cystic fibrosis. Ann Pharmacother. 1997;31(9):1003-1005.
43. Lepage G, et al. Ursodeoxycholic acid improves the hepatic metabolism of essential fatty acids and retinol in children with cystic fibrosis. J Pediatr. 1997;130(1):52-58.
44. Solomon MP, et al. Glucose intolerance in children with cystic fibrosis. J Pediatr. 2003;142(2):128-132.
45. Larsson H, Ahren B. Glucose-dependent arginine stimulation test for characterization of islet function: studies on reproducibility and priming effect of arginine. Diabetologia. 1998;41(7):772-777.
46. Pan FC, Wright C. Pancreas organogenesis: from bud to plexus to gland. Dev Dyn. 2011;240(3):530-565.
47. Garibaldi BA, Pecquet Goad ME, Fox JG, Sylvina TJ, Murray R. Serum cortisol radioimmunoassay values in the normal ferret and response to ACTH stimulation and dexamethasone suppression tests. Lab Anim Sci. 1988;38(4):452-454.
48. Duckworth WC, Bennett RG, Hamel FG. Insulin degradation: progress and potential. Endocr Rev. 1998;19(5):608-624.
49. Michael MD, et al. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol Cell. 2000; 6(1):87-97.
50. Korbutt GS, Elliott JF, Ao Z, Smith DK, Warnock GL, Rajotte RV. Large scale isolation, growth, and function of porcine neonatal islet cells. J Clin Invest. 1996;97(9):2119-2129.
51. Morino K, et al. Reduced mitochondrial density and increased IRS-1 serine phosphorylation in muscle of insulin-resistant offspring of type 2 diabetic parents. J Clin Invest. 2005;115(12):3587-3593.
52. Lee J, et al. Multiple abnormalities of myocardial insulin signaling in a porcine model of dietinduced obesity. Am J Physiol Heart Circ Physiol. 2010;298(2):H310-H319.
53. Gutierrez-Juarez R, et al. Critical role of stearoyl-CoA desaturase-1 (SCD1) in the onset of dietinduced hepatic insulin resistance. J Clin Invest. 2006; 116(6):1686-1695.
54. Morino K, et al. Muscle-specific IRS-1 Ser->Ala transgenic mice are protected from fat-induced insulin resistance in skeletal muscle. Diabetes. 2008; 57(10):2644-2651.
55. Minicucci L, et al. Liver disease as risk factor for cystic fibrosis-related diabetes development. Acta Paediatr. 2007;96(5):736-739.
56. Colombo C. Liver disease in cystic fibrosis. Curr Opin Pulm Med. 2007;13(6):529-536.
57. Lykavieris P, Bernard O, Hadchouel M. Neonatal cholestasis as the presenting feature in cystic fibrosis. Arch Dis Child. 1996;75(1):67-70.
58. Feranchak AP, Sokol RJ. Cholangiocyte biology and cystic fibrosis liver disease. Semin Liver Dis. 2001;21(4):471-488.
59. Smith BW, Adams LA. Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment. Nat Rev Endocrinol. 2011;7(8):456-465.
60. Del Prato S, Tiengo A. The importance of firstphase insulin secretion: implications for the therapy of type 2 diabetes mellitus. Diabetes Metab Res Rev. 2001;17(3):164-174.
61. Elder DA, Wooldridge JL, Dolan LM, D'Alessio DA. Glucose tolerance, insulin secretion, and insulin sensitivity in children and adolescents with cystic fibrosis and no prior history of diabetes. J Pediatr. 2007;151(6):653-658.
62. Anzeneder L, Kircher F, Feghelm N, Fischer R, Seissler J. Kinetics of insulin secretion and glucose intolerance in adult patients with cystic fibrosis. Horm Metab Res. 2011;43(5):355-360.
63. Battezzati A, et al. Spontaneous hypoglycemia in patients with cystic fibrosis. Eur J Endocrinol. 2007; 156(3):369-376.
64. Radike K, Molz K, Holl RW, Poeter B, Hebestreit H, Ballmann M. Prognostic relevance of hypoglycemia following an oral glucose challenge for cystic fibrosis-related diabetes. Diabetes Care. 2011;34(4):e43.
65. Sturgess JM. Structural and developmental abnormalities of the exocrine pancreas in cystic fibrosis. J Pediatr Gastroenterol Nutr. 1984;3(suppl 1):S55-S66.
66. Imrie JR, Fagan DG, Sturgess JM. Quantitative evaluation of the development of the exocrine pancreas in cystic fibrosis and control infants. Am J Pathol. 1979;95(3):697-708.
67. Raman VS, et al. Hyperglycemia and diabetes mellitus in children with pancreatitis. J Pediatr. 2011; 158(4):612-616e1.
68. Lucidi V, et al. The etiology of acute recurrent pancreatitis in children: a challenge for pediatricians. Pancreas. 2011;40(4):517-521.
69. Walkowiak J, Lisowska A, Blaszczynski M. The changing face of the exocrine pancreas in cystic fibrosis: pancreatic sufficiency, pancreatitis and genotype. Eur J Gastroenterol Hepatol. 2008;20(3):157-160.
70. Segal I, et al. Cystic fibrosis transmembrane conductance regulator ion channel function testing in recurrent acute pancreatitis. J Clin Gastroenterol. 2008;42(7):810-814.
71. Kulkarni RN, et al. beta-cell-specific deletion of the Igf1 receptor leads to hyperinsulinemia and glucose intolerance but does not alter beta-cell mass. Nat Genet. 2002;31(1):111-115.
72. Norris AW, et al. Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J Clin Invest. 2003;112(4):608-618.